Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-05-14 | 2025-05-14 |
| Drug Identification Number | 02306433 | 02306433 |
| Brand name | ALIMTA | ALIMTA |
| Common or Proper name | pemetrexed disodium for injection | pemetrexed disodium for injection |
| Company Name | ELI LILLY CANADA INC | ELI LILLY CANADA INC |
| Ingredients | PEMETREXED | PEMETREXED |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | Carton package containing one 10 mL vial | Carton package containing one 10 mL vial |
| ATC code | L01BA | L01BA |
| ATC description | ANTIMETABOLITES | ANTIMETABOLITES |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2026-01-30 | 2026-01-30 |
| Actual discontinuation date | ||
| Remaining supply date | 2026-01-30 | 2026-01-30 |
| Discontinuation status | To be discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | For any questions, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). | For any questions, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
| Health Canada comments |